A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing ...

Engraftment reached 100% for some microbial species known to support overall gut health and protect against graft-versus-host disease ... such as less acute GVHD, fewer hospitalizations, fewer ...

Shernan Holtan, MD, has been named the recipient of 2025 Lukas D. Wartman Award. Holtan, chief of blood and marrow ...

FDA approved Ryoncil ® as the first and only therapy for pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

Ryoncil ® was approved in December 2024 by the United States Food and Drug Administration (FDA) for steroid-refractory acute ...

More information: Swetha Reddi et al, Fecal microbiota transplantation to prevent acute graft-versus-host disease: pre-planned interim analysis of donor effect, Nature Communications (2025).

Engraftment reached 100% for some microbial species known to support overall gut health and protect against graft-versus-host disease ... such as less acute GVHD, fewer hospitalizations, fewer ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today ...